HBM Holdings Limited

HKEX:2142.HK

1.24 (HKD) • At close September 20, 2024
Bedrijfsnaam HBM Holdings Limited
Symbool 2142.HK
Munteenheid HKD
Prijs 1.24
Beurswaarde 953,406,240
Dividendpercentage 0%
52-weken bereik 1.01 - 1.98
Industrie Biotechnology
Sector Healthcare
CEO Dr. Jingsong Wang M.D., Ph.D.
Website https://www.harbourbiomed.com

An error occurred while fetching data.

Over HBM Holdings Limited

HBM Holdings Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of differentiated antibody therapeutics in immunology and oncology disease areas. It is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor; Tanfanercept (HBM9036) to treat moderate to-severe dry

Vergelijkbare Aandelen

IVD Medical Holding Limited logo

IVD Medical Holding Limited

1931.HK

1.8 HKD

Modern Dental Group Limited logo

Modern Dental Group Limited

3600.HK

3.85 HKD

IntelliCentrics Global Holdings Ltd. logo

IntelliCentrics Global Holdings Ltd.

6819.HK

4.06 HKD

Abbisko Cayman Limited logo

Abbisko Cayman Limited

2256.HK

3.12 HKD

JW (Cayman) Therapeutics Co. Ltd logo

JW (Cayman) Therapeutics Co. Ltd

2126.HK

1.37 HKD

Immunotech Biopharm Ltd logo

Immunotech Biopharm Ltd

6978.HK

2.84 HKD

Mabpharm Limited logo

Mabpharm Limited

2181.HK

0.305 HKD

China Pioneer Pharma Holdings Limited logo

China Pioneer Pharma Holdings Limited

1345.HK

2.08 HKD

Kindstar Globalgene Technology, Inc. logo

Kindstar Globalgene Technology, Inc.

9960.HK

1.22 HKD

Zhaoke Ophthalmology Limited logo

Zhaoke Ophthalmology Limited

6622.HK

1.37 HKD

Financiële Gegevens

Cijfers zijn in miljoenen (HKD)

Cijfers zijn in miljoenen (HKD)